Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

By The Northwire Desk — AI Analysis Dec 10, 2025 · 20:01 QNTM · 14.75 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • Quantum BioPharma closed a non‑brokered private placement of 30 Class A multiple‑voting shares at $25 each, generating gross proceeds of $750.
  • The shares were purchased by insiders (Xorax Family Trust and Fortius Research & Trading Corp.), resulting in updated ownership percentages for Class A and Class B securities and voting rights.
  • The company also terminated its at‑the‑market offering agreement with H.C. Wainwright & Co., LLC, and settled a $260,000 debt by issuing 17,626 Class B shares at $14.75 per share.

Key Details

  • Offering size: 30 Class A multiple‑voting shares @ $25 per share → gross proceeds $750.
  • Statutory hold period: Four months plus one day for all issued securities.
  • Use of proceeds: General working capital.
  • Related‑party participation:
  • Xorax Family Trust (beneficiary: CEO Zeeshan Saeed) purchased 15 shares for $375.
  • Fortius Research & Trading Corp. (director: Anthony Durkacz) purchased 15 shares for $375.
  • Post‑offering ownership – Class A: Xorax and Fortius each hold 21 of the total outstanding Class A shares (50% of Class A).
  • Post‑offering voting rights:
  • Xorax + Mr. Saeed control ~38.43% of total voting securities (partially diluted).
  • Fortius + Mr. Durkacz + FRCC control ~37.97% of total voting securities (partially diluted).
  • Class B holdings: Updated percentages for Class B subordinate voting shares and options/RSUs disclosed for each insider group.
  • At‑the‑market offering termination: Notice given to H.C. Wainwright & Co.; termination effective 2025‑12‑20; no Class B shares sold under the agreement (prospectus supplement allowed up to $21,225,000).
  • Debt settlement: $260,000 debt settled by issuing 17,626 Class B subordinate voting shares at a deemed price of $14.75 per share.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other